3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
10
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Central Nervous System Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oligodendroglioma
2
Melanoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Thymus Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
Paclitaxel
13
pembrolizumab
8
Carboplatin
7
Cisplatin
5
Docetaxel
4
Brachytherapy
4
Pemetrexed
3
Gemcitabine
3
Doxorubicin
3
Biopsy
3
osimertinib
2
olaparib
2
niraparib
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Topotecan
2
Taxes
2
Standard of Care
2
Sentinel Lymph Node Biopsy
2
Saline Solution
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Nivolumab
2
Music Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Letrozole
2
Immunoglobulin G
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts